| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 10/14/2004 | CA2518903A1 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| 10/14/2004 | CA2518872A1 Devices, methods, and compositions to prevent restenosis |
| 10/14/2004 | CA2518533A1 Oral suspension of tegaserod |
| 10/14/2004 | CA2518270A1 Parenteral formulation of mycophenolic acid, a salt or prodrug thereof |
| 10/14/2004 | CA2516429A1 Stable ophthalmic formulation containing an antibiotic and a corticosteroid |
| 10/13/2004 | EP1466915A1 Porphyrin compound, albumin inclusion compound thereof and artificial oxygen carrier |
| 10/13/2004 | EP1466889A1 Derivatives of venlafaxine and methods of preparing and using the same |
| 10/13/2004 | EP1466649A1 Pharmaceutical composition containing artificial oxygen carrier |
| 10/13/2004 | EP1466631A1 Preparations appropriate for cartilage tissue formation |
| 10/13/2004 | EP1466628A1 DHA-pharmaceutical agent conjugates |
| 10/13/2004 | EP1466627A1 Polyglutamate camptothecin conjugates |
| 10/13/2004 | EP1466626A1 Medicinal compositions for improving oral absorption |
| 10/13/2004 | EP1466614A1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 10/13/2004 | EP1466610A1 Medicinal compositions for nasal absorption |
| 10/13/2004 | EP1466601A2 Prevention of migraine recurrence |
| 10/13/2004 | EP1466600A1 Ready-to-use oxaliplatin solutions |
| 10/13/2004 | EP1466599A1 Concentrated solution of oxaliplatinum |
| 10/13/2004 | EP1466595A1 Apparatus and process for preparing crystalline particles |
| 10/13/2004 | EP1466594A2 Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 10/13/2004 | EP1466593A1 Biodegradable injectable implant |
| 10/13/2004 | EP1465997A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 10/13/2004 | EP1465991A1 Bioreactor |
| 10/13/2004 | EP1465989A1 Growth factor modified protein matrices for tissue engineering |
| 10/13/2004 | EP1465938A1 Dendritic poly (amino acid) carriers and methods of use |
| 10/13/2004 | EP1465933A1 Polymer conjugates |
| 10/13/2004 | EP1465926A2 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| 10/13/2004 | EP1465910A2 Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid |
| 10/13/2004 | EP1465876A1 Long chain fatty alcohol substituents in antineoplastic agents |
| 10/13/2004 | EP1465676A1 Film-forming compositions and methods |
| 10/13/2004 | EP1465670A2 Labeling targeting agents with gallium-68 and gallium-67 |
| 10/13/2004 | EP1465666A2 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| 10/13/2004 | EP1465665A1 Water-soluble stabilized self-assembled polyelectrolytes |
| 10/13/2004 | EP1465664A1 Stabilized formulations of adenovirus |
| 10/13/2004 | EP1465663A1 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent |
| 10/13/2004 | EP1465657A2 Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells |
| 10/13/2004 | EP1465652A2 Povidone-containing carriers for polypeptide growth factors |
| 10/13/2004 | EP1465643A1 Methods and compositions for oxygen transport comprising a high oxygen affinity |
| 10/13/2004 | EP1465637A1 25-hydroxy vitamin d3 compositions |
| 10/13/2004 | EP1465636A2 Compositions and methods for enhancing corticosteriod delivery |
| 10/13/2004 | EP1465628A2 Fine particle size pioglitazone |
| 10/13/2004 | EP1465617A1 Process for affecting neurologic progression |
| 10/13/2004 | EP1465606A2 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 10/13/2004 | EP1465604A1 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| 10/13/2004 | EP1465602A1 Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen |
| 10/13/2004 | EP1465600A1 Particulate compositions comprising a lipophilic liquid |
| 10/13/2004 | EP1465599A1 Liposome composition for delivery of nucleic acid |
| 10/13/2004 | EP1465598A1 Use of oligomers and polymers for drug solublization, stabilization, and delivery |
| 10/13/2004 | EP1465596A1 Polymeric gel system for the controlled delivery of codrugs |
| 10/13/2004 | EP1465594A1 Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof |
| 10/13/2004 | EP1465593A1 Solid orally-dispersible pharmaceutical formulation |
| 10/13/2004 | EP1465592A2 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 10/13/2004 | EP1465582A1 Alkyl- and/or alkylene oligoglycoside betaine ester quaternaries |
| 10/13/2004 | EP1465505A2 Stimulation of the immune system with polydextrose |
| 10/13/2004 | EP1465504A1 Matrix-forming composition containing pectin |
| 10/13/2004 | EP1465498A1 Center-filled chewing gum containing calcium |
| 10/13/2004 | EP1465493A1 Cultured and encapsulated pancreatic stem cells |
| 10/13/2004 | EP1465491A1 Antiseptic compositions and methods |
| 10/13/2004 | EP1313510B1 Injectable pharmaceutical composition for systemic delivery of pharmacologically active compounds comprising medium chain triglycerides |
| 10/13/2004 | EP1289515B1 Pharmaceutical composition containing at least a polymer associated or conjugated with at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof |
| 10/13/2004 | EP1267884B1 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients |
| 10/13/2004 | EP1261346A4 Modulation of cardiovascular injury |
| 10/13/2004 | EP1207866B1 Delayed-action form of administration containing tramadol saccharinate |
| 10/13/2004 | EP1206253B1 Pharmaceutical preparations containing nanosols of chitosan, and their preparation |
| 10/13/2004 | EP1177217B1 Amphiphile cyclodextrins, preparation and use thereof for solubilising organised systems and incorporating hydrophobic molecules |
| 10/13/2004 | EP1135166B1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 10/13/2004 | EP1131340B1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 10/13/2004 | EP1128831B1 Pharmaceutical moxifloxacin preparation |
| 10/13/2004 | EP1093383B1 Drug delivery system comprising a homeobox peptide and a cytotoxic or antineoplastic drug |
| 10/13/2004 | EP1087786B1 Methods and materials for the treatment of prostatic carcinoma |
| 10/13/2004 | EP1062230B1 Method for increasing the serum half-life of a biologically active molecule |
| 10/13/2004 | EP0973818B1 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |
| 10/13/2004 | EP0637933B1 Method for treating organs and tissues |
| 10/13/2004 | CN1537117A 干扰素γ多肽变体 IFN-γ polypeptide variant |
| 10/13/2004 | CN1537015A Stable liquid formulations of antibodies |
| 10/13/2004 | CN1537007A 2 methyl-thieno-benzodiazepine lyophilizde formulation |
| 10/13/2004 | CN1537003A Pharmaceutical composition comprising tricyclic compound for prevention or treatment of skin diseases |
| 10/13/2004 | CN1536998A Integrin inhibitors for treatment of eye diseases |
| 10/13/2004 | CN1536997A Crystalline composition containing escitalopram |
| 10/13/2004 | CN1536993A Solid pharmaceutical composition comprising 4-cyano-trifluoro-N-[3-(40fluorophenylsulphonyl)2-hydroxy-2-methylpropiono]-m-toluidide and PVP |
| 10/13/2004 | CN1536991A (f)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 10/13/2004 | CN1536987A Sustained-release suspension of ceftiofur hydrochloride |
| 10/13/2004 | CN1536986A Intravaginal drug delivery devices for administration of antimicrobial agent |
| 10/13/2004 | CN1535680A Abidor inclusion compound |
| 10/13/2004 | CN1170595C Use of hydroxylated carboxylate or amide used as solubilizing agent |
| 10/13/2004 | CN1170591C Pharmaceutical prepn. contg. fibrinolysin activators |
| 10/13/2004 | CN1170586C Pharmaceutical formulation of Didemnin compound |
| 10/13/2004 | CN1170584C Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
| 10/13/2004 | CN1170543C Use of PEG-IFN-alpha and triazloe nucleoside for treatment of chronic hepatitis C |
| 10/13/2004 | CN1170541C Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors |
| 10/13/2004 | CN1170540C Sustained-release theophylline tablet |
| 10/13/2004 | CN1170539C Antifungal oral composition containing itraconazole and process for preparing same |
| 10/13/2004 | CN1170534C Pharmaceutical compositions containing lipase inhibitors |
| 10/13/2004 | CN1170533C Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 10/13/2004 | CN1170530C Patch containing 4-biphenylacetic acid |
| 10/13/2004 | CN1170527C Therapeutic perparation for inhalation containing parathyroid hormone, PTH |
| 10/13/2004 | CN1170525C Method for producing solid dosing forms |
| 10/13/2004 | CN1170524C Fentanyl composition for treatment of acute pain |
| 10/13/2004 | CN1170523C Sustained-release drug formulations for implantation |
| 10/13/2004 | CN1170517C Water-containing powder composition and process for producing same and cosmetic preparation containing powder composition |
| 10/12/2004 | US6803438 Uniform molecular weight polymers |